Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Best

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|November 10, 2009
Epigenetic opportunities and challenges in cancerJonathan D Best, Nessa Carey
Obstetric Medicine|March 1, 2013
The Epigenetics of Normal PregnancyJonathan D Best, Nessa Carey
Drug Discovery Today|October 27, 2010
Epigenetic therapies for non-oncology indicationsJonathan D Best, Nessa Carey
Current Biology : CB|April 9, 2002
Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cellsGiles E Duffield, Jonathan D Best, Bernhard H Meurers, et al.
Journal of Neuroscience Methods|July 25, 2006
A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brainJulian L Goggi, Huw D Lewis, Joanie Mok, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 22, 2007
Non-associative learning in larval zebrafishJonathan D Best, Stéphane Berghmans, Julia J F G Hunt, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 31, 2006
In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the ratJonathan D Best, Mark T Jay, Franklin Otu, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 4, 2005
Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]Jonathan D Best, Mark T Jay, Franklin Otu, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane coreStephen J Lewis, Adrian L Smith, Joseph G Neduvelil, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 14, 2006
The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouseJonathan D Best, David W Smith, Michael A Reilly, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|November 10, 2009
Epigenetic opportunities and challenges in cancerJonathan D Best, Nessa Carey
Obstetric Medicine|March 1, 2013
The Epigenetics of Normal PregnancyJonathan D Best, Nessa Carey
Drug Discovery Today|October 27, 2010
Epigenetic therapies for non-oncology indicationsJonathan D Best, Nessa Carey
Current Biology : CB|April 9, 2002
Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cellsGiles E Duffield, Jonathan D Best, Bernhard H Meurers, et al.
Journal of Neuroscience Methods|July 25, 2006
A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brainJulian L Goggi, Huw D Lewis, Joanie Mok, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 22, 2007
Non-associative learning in larval zebrafishJonathan D Best, Stéphane Berghmans, Julia J F G Hunt, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 31, 2006
In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the ratJonathan D Best, Mark T Jay, Franklin Otu, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 4, 2005
Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]Jonathan D Best, Mark T Jay, Franklin Otu, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane coreStephen J Lewis, Adrian L Smith, Joseph G Neduvelil, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 14, 2006
The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouseJonathan D Best, David W Smith, Michael A Reilly, et al.
Pageof 2